APA (7th ed.) Citation

ML, B., G, F., M, D. M., P, C., D, R., M, M., . . . F, P. (2025). Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy. Bone marrow transplantation, 60(10), 1406. https://doi.org/10.1038/s41409-025-02674-3

Chicago Style (17th ed.) Citation

ML, Battista, et al. "Real-world Study in Steroid-refractory Acute Graft Versus Host Disease: Comparison of Efficacy and Tolerability of Ruxolitinib Alone or Ruxolitinib in Association with Extracorporeal Photopheresis or Extracorporeal Photopheresis Monotherapy." Bone Marrow Transplantation 60, no. 10 (2025): 1406. https://doi.org/10.1038/s41409-025-02674-3.

MLA (9th ed.) Citation

ML, Battista, et al. "Real-world Study in Steroid-refractory Acute Graft Versus Host Disease: Comparison of Efficacy and Tolerability of Ruxolitinib Alone or Ruxolitinib in Association with Extracorporeal Photopheresis or Extracorporeal Photopheresis Monotherapy." Bone Marrow Transplantation, vol. 60, no. 10, 2025, p. 1406, https://doi.org/10.1038/s41409-025-02674-3.